Scientific Exchange International Conference on Hodgkin Lymphoma - Optimal Management in Relapsed/Refractory HL - Relacje cyfrowe

Long term response to BV treatment in case of HD

Pluta Andrzej

Long term response to BV treatment in case of HD
Long-term response to treatment with brentuximab vedotin in a patient with relapse of Hodgkin’s lymphoma after auto-SCT - (case report)

Subocz Edyta

Long-term response to treatment with brentuximab vedotin in a patient with relapse of Hodgkin’s lymphoma after auto-SCT - (case report)
Polish experience with brentuximab vedotin

Czyż Anna

Polish experience with brentuximab vedotin
Considering consolidation after ASCT

Paszkiewicz-Kozik Ewa

Considering consolidation after ASCT
Emerging new therapies for R/R Hodgkin lymphoma

Jurczak Wojciech

Emerging new therapies for R/R Hodgkin lymphoma
AlloSCT for HL after autoSCT failure

Giebel Sebastian

AlloSCT for HL after autoSCT failure
Jak interpretować wynik badania PET/CT w przypadku chłoniaka Hodgkina

Małkowski Bodgan

Jak interpretować wynik badania PET/CT w przypadku chłoniaka Hodgkina
Clinical approach to PET in Hodgkin Lymphoma

Wróbel Tomasz

Clinical approach to PET in Hodgkin Lymphoma
Relapsed / Refractory Hodgkin’s Lymphoma after Autologous Hematopoietic Stem Cell Transplantation. The Non-Allotransplant Approach

Sureda Anna

Relapsed / Refractory Hodgkin’s Lymphoma after Autologous Hematopoietic Stem Cell Transplantation. The Non-Allotransplant Approach
The status of Relapsed and Primary Refractory Hodgkin Lymphoma-2019

Moskowitz Craig

The status of Relapsed and Primary Refractory Hodgkin Lymphoma-2019
Debata podsumowująca konferencję SEIC-HL

hematoonkologia.pl

Debata podsumowująca konferencję SEIC-HL
SEIC-HL - reportaż z wydarzenia

hematoonkologia.pl

SEIC-HL - reportaż z wydarzenia